May 4, 2024
Loading...
You are here:  Home  >  Subscriber content  -  Page 21
Latest

MannKind looks to clear up debt with capital from royalty agreement

By   /  Thursday, January 4th, 2024  /  Health Care & Life Science, Latest news, middle, Subscriber content, Tri-County Economy, Tri-County Public Companies  /  Comments Off on MannKind looks to clear up debt with capital from royalty agreement

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Region’s top stocks look to dominate their industries

By   /  Thursday, January 4th, 2024  /  Central Coast, Latest news, left, Subscriber content, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Region’s top stocks look to dominate their industries

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Limoneira pleased by FY2023 despite revenue dip

By   /  Thursday, December 28th, 2023  /  Agribusiness, Earnings, Regions, Subscriber content, Top Stories, Top Story, Tri-County Public Companies, Ventura County  /  Comments Off on Limoneira pleased by FY2023 despite revenue dip

Despite a 2.5% dip in fiscal year 2023 revenues compared to fiscal year 2022, the CEO of Santa Paula-based Limoneira says he’s pleased with the agribusiness’s year-over-year performance. “We achieved our full-year avocado and revised lemon volume guidance despite harsh weather conditions and softer lemon pricing throughout most of the year,” Harold Edwards said during Read More →

Latest

CRE: Two multi-family apartments in Thousand Oaks sold for $171M

By   /  Tuesday, December 26th, 2023  /  Columns, Latest news, Real Estate, Subscriber content  /  Comments Off on CRE: Two multi-family apartments in Thousand Oaks sold for $171M

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Tri-County travel industry rebounds from pandemic

By   /  Tuesday, December 26th, 2023  /  Central Coast, Columns, Latest news, middle, Subscriber content, Tri-County Economy  /  Comments Off on Tri-County travel industry rebounds from pandemic

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Street smarts: Santa Barbara company donates equipment

By   /  Tuesday, December 26th, 2023  /  Columns, Latest news, Nonprofits, Philanthropy, Subscriber content, Tri-County Economy  /  Comments Off on Street smarts: Santa Barbara company donates equipment

Santa Barbara-based MOS Equipment held a special event on Dec. 21 dedicated to enhancing the capabilities of local law enforcement agencies in digital forensics. The company donated its Mission Darkness faraday bags and analysis enclosures to the agencies, with each kit valued at approximately $11,000. AWARDS SEASON The Ventura County Chapter of SCORE recognized two local Read More →

Latest

Arcutis’ treatment gets additional FDA approval

By   /  Friday, December 22nd, 2023  /  Health Care & Life Science, Latest news, Subscriber content, Top Stories, Top Story, Tri-County Economy  /  Comments Off on Arcutis’ treatment gets additional FDA approval

Westlake Village-based Arcutis Biotherapeutics announced that its main treatment option, Zoryve, received approval from the U.S. Drug and Food Administration for treating a skin condition called seborrheic dermatitis, the company announced on Dec. 15 It is the second FDA approval received by Arcutis’ Zoryve, being approved to be used in individuals nine years of age Read More →